Amrit Baral, PhD, MBBS, MPH
Johns Hopkins University Bloomberg School of Public Health
Johns Hopkins University Bloomberg School of Public Health,
1812 Ashland Ave,
Baltimore MD, 21205
Dr. Amrit Baral is an epidemiologist and physician-scientist, with a Ph.D. in Epidemiology from the University of Miami Miller School of Medicine and medical training from Chongqing Medical University, China. Currently, he is a NIDA T32 Postdoctoral Research Fellow in the Department of Mental Health at Johns Hopkins Bloomberg School of Public Health. Dr. Baral’s current research focuses on cannabis hyperemesis syndrome (CHS), route-specific patterns of cannabis use and their association with cannabis use disorder (CUD), and the cardiometabolic and sleep-related health effects of cannabis use in occupational settings. Using large national survey data and electronic health records, he examines how patterns and contexts of cannabis use translate into clinical and population-level health outcomes.
Dr. Baral received his Master of Public Health degree from West Chester University of Pennsylvania. Born and raised in Pokhara, Nepal, he practiced clinical medicine in Nepal before transitioning to a career in public health and research in the United States. His research interest lies on exploring the biological, behavioral, and societal effects of cannabis and psychedelics on human health and disease through a comprehensive “cells-to-society” approach. Passionate about conceptualizing, designing, and implementing rigorous epidemiological studies, Dr. Baral aims to elucidate the role of alternative and integrative medicine—particularly cannabis and classic psychedelics—in promoting health and addressing chronic disease. Dr. Baral is a founding member of the Global Cannabis and Psychedelics Research Collaboratory at the University of Miami in Florida.
He served as the Lead Biostatistician for the Herbal Heart Study, a National Heart, Lung, and Blood Institute (NHLBI)-funded R01 investigation examining the effects of cannabis, cannabinoids, and routes of administration on sub-clinical cardiovascular risk. He also served as the Study Coordinator for an NCI-funded project at Sylvester Comprehensive Cancer Center that investigates patterns of cannabis and psychedelics use among cancer patients. Beyond academia, Dr. Baral is committed to community health. As a founding member and former Health Services Coordinator of Dirghayu Nepal, a non-profit organization, he led numerous initiatives to organize free medical camps, public health awareness campaigns, and health promotion programs in underserved rural areas of Nepal.
There is a vast amount of work still to be done in cannabis and psychedelics research, and Dr.Baral is eagerly open to new collaborations and learning from you. You can explore his research via Google Scholar. You’re welcome to contact Dr. Baral directly at [email protected].
latest posts
selected publications
- Experiences and Comfort of Young Cancer Patients Discussing Cannabis with Their Providers: Insights from a Survey at an NCI-Designated Cancer CenterJournal of cancer education, 2025
- State of the science: health care provider communication of Cannabis use among adults living with cancerJournal of cancer education, 2025
- Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and olderScientific Reports, 2025
- Prevalence of metabolic syndrome among emerging adult cannabis users by race/ethnicity: analysis of the 2009-2018 National Health and Nutrition Examination SurveysAmerican Journal of Medicine Open, 2024
- Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI-Designated Cancer CenterCancer Medicine, 2024
- Perceptions, attitudes, and knowledge of cannabis and its use: a qualitative study among herbal heart study young adult cannabis consumers in south FloridaPreventive medicine reports, 2024
- The prognostic role of cigarette smoking in Kidney Cancer SurvivalCancer medicine, 2023